The issuance of the US patent strengthens PharmaTher’s intellectual property portfolio covering novel uses and dosage forms of ketamine

Announcement of positive efficacy and safety data from a phase 1/2 clinical trial of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, with 100% of ketamine-treated patients demonstrating a reduction in dyskinesia as measured by the Unified Dyskinesia Rating Scale reductions of 51% from baseline during infusion 2 (p=0.003), 49% at 3 weeks (p=0.006), and 41% at 3 months (p=0.011) after ketamine

Planning a Phase 3 clinical trial to allow FDA approval of KETARX™ (ketamine) for Parkinson’s disease under route 505(b)(2).

TORONTO, Oct. 5, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) PHRRF PHRMa specialty pharmaceutical company focused on the development and commercialization of novel uses and delivery modes of ketamine for the treatment of psychiatric, neurological and pain disorders, is pleased to announce that the United States Patent and Trademark Office (“USPTO”) Patent No. 11,426,366 entitled “Compositions and Methods for Treating Motor Disorders,” which includes claims aimed at covering ketamine in the potential treatment of Parkinson’s disease and motor disorders involving involuntary or uncontrollable movements or actions of the body (the “Patent”).

Fabio Chianelli, CEO of PharmaTher, commented: “We are pleased to receive the USPTO patent for ketamine in the treatment of Parkinson’s disease and motor disorders. The US patent strengthens our intellectual property portfolio, which includes novel uses and dosage forms of ketamine. We are advancing the clinical development of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, and we are seeking FDA approval for approval under regulatory pathway 505(b)(2) with a potential clinical phase 3 study.”

On September 16, 2022, the Company…